Bio-Rad Laboratories 

$309.37
117
+$10.87+3.64% Monday 15:55

Statistics

Day High
309.37
Day Low
309.37
52W High
321.12
52W Low
244.54
Volume
91
Avg. Volume
116
Mkt Cap
6.71B
P/E Ratio
49.75
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
1.73
2.12
2.51
2.9
Expected EPS
1.747616
Actual EPS
N/A

Financials

-71.86%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2.57BRevenue
-1.84BNet Income

Analyst Ratings

303.33Average Price Target
The highest estimate is 320.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIO-B. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap195.86B
Thermo Fisher Scientific offers a broad range of products and services in the life sciences sector, directly competing with Bio-Rad's offerings in laboratory equipment and consumables.
Danaher
DHR
Mkt Cap140.88B
Danaher Corporation operates in similar segments as Bio-Rad, including life sciences and diagnostics, making them direct competitors in multiple product lines.
Illumina
ILMN
Mkt Cap28.78B
Illumina specializes in genomics and DNA sequencing technologies, competing with Bio-Rad's products in the genomics field.
Agilent Technologies
A
Mkt Cap37.93B
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Bio-Rad Laboratories
BIO.B
Mkt Cap8.84B
Bio-Rad Laboratories Class B shares represent a different class of stock of the same company but are listed separately, directly tied to the company's performance.
Waters
WAT
Mkt Cap36.96B
Waters Corporation provides analytical instruments for the life sciences sector, competing with Bio-Rad's chromatography and mass spectrometry products.
Bruker
BRKR
Mkt Cap9.14B
Bruker Corporation is a competitor in the life science analytical and diagnostic instruments sector, directly competing with several of Bio-Rad's product lines.
Qiagen NV
QGEN
Mkt Cap8.56B
QIAGEN is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing with Bio-Rad in the diagnostics and research sectors.
Baxter International
BAX
Mkt Cap11.68B
Baxter International operates in the medical devices and life sciences fields, competing with Bio-Rad in the broader healthcare and scientific research sectors.

About

Bio-Rad Laboratories, Inc. creates, manufactures, and markets products essential for life science research and clinical diagnostics. Its operations span globally, covering territories such as the United States, Europe, Asia, Canada, and Latin America. The company's business is organized into two main divisions: Life Science and Clinical Diagnostics. The Life Science division develops and provides a comprehensive array of reagents, laboratory apparatus, and instruments. These are vital for various applications, including scientific research methodologies, biopharmaceutical production processes, and food quality testing. This segment dedicates its efforts to key areas within the life sciences, such as proteomics, genomics, biopharmaceutical development, cellular biology, and ensuring food safety. Its diverse clientele includes academic institutions (universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology researchers, and both food producers and testing laboratories. Conversely, the Clinical Diagnostics division specializes in designing, producing, selling, and supporting diagnostic test systems, informatics solutions, test kits, and specific quality control measures for clinical laboratories. This segment furnishes reagents, instrumentation, and software precisely tailored to address particular requirements within the in vitro diagnostics market. Its products are utilized by reference laboratories, hospital labs, state-operated newborn screening facilities, physicians' private offices, and blood transfusion centers. Furthermore, Bio-Rad offers systems and products designed for separating intricate chemical and biological substances, as well as for identifying, analyzing, and purifying their individual components. The company distributes its offerings through a multi-channel approach, leveraging both its direct sales force and a network of distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was established in 1952 and its corporate headquarters are located in Hercules, California.
Show more...
CEO
Mr. Norman D. Schwartz
Employees
7700
Country
United States
ISIN
US0905721082

Listings

0 Comments

Share your thoughts

FAQ

What is Bio-Rad Laboratories stock price today?
The current price of BIO-B is $309.37 USD — it has increased by +3.64% in the past 24 hours. Watch Bio-Rad Laboratories stock price performance more closely on the chart.
What is Bio-Rad Laboratories stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Bio-Rad Laboratories stocks are traded under the ticker BIO-B.
What is Bio-Rad Laboratories market cap?
Today Bio-Rad Laboratories has the market capitalization of 6.71B
When is the next Bio-Rad Laboratories earnings date?
Bio-Rad Laboratories is going to release the next earnings report on July 30, 2026.
What were Bio-Rad Laboratories earnings last quarter?
BIO-B earnings for the last quarter are 1.89 USD per share, whereas the estimation was 1.97 USD resulting in a -4.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bio-Rad Laboratories revenue for the last year?
Bio-Rad Laboratories revenue for the last year amounts to 2.57B USD.
What is Bio-Rad Laboratories net income for the last year?
BIO-B net income for the last year is -1.84B USD.
How many employees does Bio-Rad Laboratories have?
As of July 18, 2026, the company has 7,700 employees.
In which sector is Bio-Rad Laboratories located?
Bio-Rad Laboratories operates in the Health & Wellness sector.
When did Bio-Rad Laboratories complete a stock split?
Bio-Rad Laboratories has not had any recent stock splits.
Where is Bio-Rad Laboratories headquartered?
Bio-Rad Laboratories is headquartered in Hercules, United States.